CAS: 1780-72-9; 4-Bromo-5-Methyl-1H-Pyrazol-3-Amine

该化合物是一种有机化合物,其特点是其配子环结构,由五人组成,内含两个氮原子的环形结构;四点方位的溴原子和五点方位的甲基组的存在,会助长其独特的化学特性;该化合物一般会由于有可参与氢结合的amin功能组的存在而在极地溶剂中表现出中等溶解性;它可能参与各种化学反应,包括核分裂替代和混合反应,使其在合成有机化学中有用;此外,这种化合物可能具有生物活动,有可能作为制药或农用化学品合成的中间体;在处理时,应参考安全数据,因为卤化化合物可能对环境和健康造成危害;

结构式图片

相似化合物

70951-96-1 16461-94-2 154787-28-7

欧盟法规

ECHA物质C&L通报

上下游产品

CAS号4027-56-9 5-Methyl-1H-pyr... | CAS号32258-58-5 4-溴-5-甲基-1H-吡唑-3-甲酰胺

合成工艺路线路线简述

    📜3-氨基-5-甲基吡唑置于n-溴代丁二酰亚胺(Nbs)体系中,化学反应生成5-氨基-4-溴-3-甲基-1H-吡唑
    参考文献:P-Tsa 催化 5-氨基吡唑和 3°/2°-炔丙醇的 6-Endo-Trig/dig 环化:吡唑并[1,5-A]二氢嘧啶和吡唑并[3,4-B]吡啶的获取
    标题:P-Tsa 催化 5-氨基吡唑和 3°/2°-炔丙醇的 6-Endo-Trig/dig 环化:吡唑并[1,5-A]二氢嘧啶和吡唑并[3,4-B]吡啶的获取
    摘要:通过在 P-Tsa 存在下使用 5-氨基吡唑,3°/2°-炔丙醇和烯酮,可以简单,直接地合成熔合吡唑并[1,5-A]二氢嘧啶和吡唑并[3,4-B]吡啶.反应通过 5-氨基吡唑的烯丙基化(n-烷基化)/炔丙基化(c-烷基化)进行,然后进行分子内 6-Endo-Trig/dig 环化,导致标题产物形成新的 C-N 和 C-C 键.该方案的优点是操作简单的反应条件,廉价的试剂,更高的产量和克级合成.
    Doi:10.1039/d4Ob01255K

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    参考文献:10.1126/science.abo7201
    摘要:Boby ML, Fearon D, Ferla M, Filep M, Koekemoer L, Robinson MC; COVID Moonshot Consortium‡, Chodera JD, Lee AA, London N, von Delft A, von Delft F, Achdout H, Aimon A, Alonzi DS, Arbon R, Aschenbrenner JC, Balcomb BH, Bar-David E, Barr H, Ben-Shmuel A, Bennett J, Bilenko VA, Borden B, Boulet P, Bowman GR, Brewitz L, Brun J, Bvnbs S, Calmiano M, Carbery A, Carney DW, Cattermole E, Chang E, Chernyshenko E, Clyde A, Coffland JE, Cohen G, Cole JC, Contini A, Cox L, Croll TI, Cvitkovic M, De Jonghe S, Dias A, Donckers K, Dotson DL, Douangamath A, Duberstein S, Dudgeon T, Dunnett LE, Eastman P, Erez N, Eyermann CJ, Fairhead M, Fate G, Fedorov O, Fernandes RS, Ferrins L, Foster R, Foster H, Fraisse L, Gabizon R, García-Sastre A, Gawriljuk VO, Gehrtz P, Gileadi C, Giroud C, Glass WG, Glen RC, Glinert I, Godoy AS, Gorichko M, Gorrie-Stone T, Griffen EJ, Haneef A, Hassell Hart S, Heer J, Henry M, Hill M, Horrell S, Huang QYJ, Huliak VD, Hurley MFD, Israely T, Jajack A, Jansen J, Jnoff E, Jochmans D, John T, Kaminow B, Kang L, Kantsadi AL, Kenny PW, Kiappes JL, Kinakh SO, Kovar B, Krojer T, La VNT, Laghnimi-Hahn S, Lefker BA, Levy H, Lithgo RM, Logvinenko IG, Lukacik P, Macdonald HB, MacLean EM, Makower LL, Malla TR, Marples PG, Matviiuk T, McCorkindale W, McGovern BL, Melamed S, Melnykov KP, Michurin O, Miesen P, Mikolajek H, Milne BF, Minh D, Morris A, Morris GM, Morwitzer MJ, Moustakas D, Mowbray CE, Nakamura AM, Neto JB, Neyts J, Nguyen L, Noske GD, Oleinikovas V, Oliva G, Overheul GJ, Owen CD, Pai R, Pan J, Paran N, Payne AM, Perry B, Pingle M, Pinjari J, Politi B, Powell A, Pšenák V, Pulido I, Puni R, Rangel VL, Reddi RN, Rees P, Reid SP, Reid L, Resnick E, Ripka EG, Robinson RP, Rodriguez-Guerra J, Rosales R, Rufa DA, Saar K, Saikatendu KS, Salah E, Schaller D, Scheen J, Schiffer CA, Schofield CJ, Shafeev M, Shaikh A, Shaqra AM, Shi J, Shurrush K, Singh S, Sittner A, Sjö P, Skyner R, Smalley A, Smeets B, Smilova MD, Solmesky LJ, Spencer J, Strain-Damerell C, Swamy V, Tamir H, Taylor JC, Tennant RE, Thompson W, Thompson A, Tomásio S, Tomlinson CWE, Tsurupa IS, Tumber A, Vakonakis I, van Rij RP, Vangeel L, Varghese FS, Vaschetto M, Vitner EB, Voelz V, Volkamer A, Walsh MA, Ward W, Weatherall C, Weiss S, White KM, Wild CF, Witt KD, Wittmann M, Wright N, Yahalom-Ronen Y, Yilmaz NK, Zaidmann D, Zhang I, Zidane H, Zitzmann N, Zvornicanin SN. Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors. Science. 2023 Nov 10;382(6671):eabo7201.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知